1. Inicio
  2. Proyectos y Estudios
  3. ESTUDIO FASE II, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, PARA COMPARAR LA EFICACIA Y TOLERABILIDAD DE FULVESTRANT (FASLODEXTM) 500MG CON PLACEBO Y FULVESTRANT (FASLODEXTM) 500MG EN COMBINACIÓN CON EL PD-0332991 (PALBOCICLIB) COMO PRIMERA LÍNEA DE TRATAMIENTO PARA PACIENTES POSTMENOPÁUSICAS CON CÁNCER DE MAMA METASTÁSICO Y RECEPTORES HORMONALES POSITIVOS, QUE HAN COMPLETADO AL MENOS 5 AÑOS DE TRATAMIENTO ADYUVANTE ENDOCRINO Y QUE PERMANECEN LIBRES DE ENFERMEDAD POR MÁS DE 12 MESES.

ESTUDIO FASE II, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, PARA COMPARAR LA EFICACIA Y TOLERABILIDAD DE FULVESTRANT (FASLODEXTM) 500MG CON PLACEBO Y FULVESTRANT (FASLODEXTM) 500MG EN COMBINACIÓN CON EL PD-0332991 (PALBOCICLIB) COMO PRIMERA LÍNEA DE TRATAMIENTO PARA PACIENTES POSTMENOPÁUSICAS CON CÁNCER DE MAMA METASTÁSICO Y RECEPTORES HORMONALES POSITIVOS, QUE HAN COMPLETADO AL MENOS 5 AÑOS DE TRATAMIENTO ADYUVANTE ENDOCRINO Y QUE PERMANECEN LIBRES DE ENFERMEDAD POR MÁS DE 12 MESES.

Datos básicos

Código:
GEICAM/2014-12
Protocolo:
GEICAM/2014-12
EUDRACT:
2015-002437-21
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2016
Año de finalización:
2019
ENSAYO CLÍNICO NACIONAL

Objetivos del proyecto

Observaciones: Estado Comité: ACTIVO

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

GEICAM

Resultados del Ensayo Clínico

[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence

Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda

Editorial Material. 10.1016/j.farma.2024.08.009. 2024

  • Open Access.

[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Andrés JLP, Solsona MDE

Article. 10.1016/j.farma.2023.10.004. 2024


[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024


[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.09.006. 2024

  • Open Access.

2017 SEOM guidelines: a multidisciplinary approach

Santaballa, A, Vera, R

Editorial Material. 10.1007/s12094-018-1830-7. 2018


2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11611. 2021


A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

de la Fuente, Ana; (...); Ravassa, Susana

Article. 10.3390/cancers14122941. 2022


A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trial-A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.

Perez-Fidalgo, JA; (...); Gonzalez-Martin, A

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.TPS5610. 2018


A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022


A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022


A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.

de Andrés-Nogales F; (...); Martínez-Olmos J

Article. 10.1007/s41669-020-00201-2. 2020


A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.

Casado, MA; (...); Grp MULTIDEX-EMD

Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018


A new definition and refocus of pharmaceutical care: the Barbate Document

Morillo-Verdugo R; (...); Poveda-Andrés JL

Article. 10.7399/fh.11389. 2020


A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)

Llombart-Cussac, A; (...); Albanell, J

Meeting Abstract. 2021


A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.

Gavilá J; (...); Llombart-Cussac A

Article. 10.1007/s12094-019-02145-4. 2020


A Smart Digital Health Platform to Enable Monitoring of Quality of Life and Frailty in Older Patients with Cancer: A Mixed-Methods, Feasibility Study Protocol.

Papachristou, Nikolaos; (...); Bamidis, Panagiotis D.

Article. 10.1016/j.soncn.2023.151437. 2023


Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Ballesta-López O; (...); Poveda-Andrés JL

Article. 10.1177/1078155220915953. 2020


Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution

Bruixola, G; (...); Aparicio, J

Article. 10.5301/tj.5000344. 2015


Analysing criteria for price and reimbursement of orphan drugs in Spain.

Badia, X; (...); Tort, M

Article. 10.7399/fh.11147. 2019


Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/10781552211038518. 2021


ANALYSIS OF THE CLINICAL EXPERIENCE WITHIN RUCAPARIB'S EARLY ACCESS PROGRAM IN SPAIN - A GEICO STUDY

Yubero-Esteban, A.; (...); Gonzalez-Martin, A.

Meeting Abstract. 10.1136/ijgc-2021-ESGO.398. 2021


Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).

Tavira B; (...); González-Martín A

Article. 10.1158/1078-0432.CCR-23-0771. 2024


Anthracycline mediated cardiotoxicity: Detection of miRNA based early biomarkers for the prediction of myocardial injury. Hecatos study

Coloma, C. Salvador; (...); Santaballa, A.

Meeting Abstract. 10.1093/annonc/mdw365.69. 2016


Antimicrobial stewardship programme implementation in a medical ward

Ruiz, J; (...); Poveda, JL

Article. 2018


Antimicrobial stewardship programme in critical care medicine: A prospective interventional study

Ruiz, J; (...); Catellanos, A

Article. 10.1016/j.medin.2017.07.002. 2018


Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023


Assessment of the quality of sample labelling for clinical research.

Pérez-Huertas P; (...); Poveda-Andrés JL

Article. 10.7399/fh.2016.40.2.9753. 2016


Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial

Martin, A. Gonzalez; (...); Selle, F.

Meeting Abstract. 10.1016/j.annonc.2023.10.031. 2023


Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Gonzalez-Martin, Antonio; (...); Selle, Frederic

Article. 10.1200/JCO.24.00668. 2024


Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021


Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2018.12.027. 2019


Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022


BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population

Perez-Huertas, P; (...); Poveda-Andres, JL

Article. 10.1177/1043454216631952. 2017


Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience

Garcia-Robles, AA; (...); Fernandez-Navarro, JM

Meeting Abstract. 2017


Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations.

López-Fernández T; (...); López Sendón Henchel JL

Article. 10.1016/j.rec.2016.12.041. 2017


Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.

Perez-Fidalgo, Jose Alejandro; (...); Gonzalez-Martin, Antonio

Article. 10.1136/ijgc-2022-004028. 2023


Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO.

Yubero-Esteban, Alfonso; (...); Sanchez Lorenzo, Maria Luisa

Meeting Abstract. 2022


Clinical insights from the rucaparib access program in Spain: A sub-analysis of long-term responders by GEICO.

Yubero-Esteban, Alfonso; (...); Gonzalez Martin, Antonio

Meeting Abstract. 2022


Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019


Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Megias-Vericat, JE; (...); Poveda, JL

Meeting Abstract. 2020


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023


COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

  • Open Access.

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024


Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1080/13696998.2017.1311903. 2017


Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020


COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018


COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020


Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021


Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1111/hae.13733. 2019


Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019


Current Status of Cardio-Oncology in Spain: A National Multidisciplinary Survey.

Martín-García A; (...); López-Fernández T

Letter. 10.1016/j.rec.2017.11.002. 2019


Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024


Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2-metastatic breast cancer from the GEICAM/2013-02 PEARL study

Guerrero, Angel; (...); Martin, Miguel

Meeting Abstract. 2023


Characterization of the gene expression profile of breast cancer tumours in patients undergoing ovarian stimulation for fertility preservation purposes

Soriano, M. J.; (...); Diaz-Garcia, C.

Meeting Abstract. 2022


Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.1080/17512433.2019.1573668. 2019


Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018


Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021


Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019


DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019


Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024


Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024


DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019


Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019


Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients

Salvador-Coloma, C; (...); Santaballa, A

Meeting Abstract. 2018


Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases

Megias-Vericat, JE; (...); Poveda, JL

Review. 10.1007/s10072-017-2833-9. 2017


Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations

Salvador-Coloma, C; (...); Juan, O

Article. 10.21037/jtd.2018.02.30. 2018


Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018


Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020


Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021


Effectiveness of group therapy in women with localized breast cancer

Bellver-Perez, A, Peris-Juan, C, Santaballa-Beltran, A

Article. 10.1016/j.ijchp.2019.02.001. 2019


Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)

Rubio, MJ; (...); Santaballa, A

Article. 10.1016/j.gore.2020.100594. 2020


Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.

Garcia, YG; (...); Gonzalez Martin A

Article. 10.1136/ijgc-2019-000256. 2019


EFFICACY OF TRABECTEDIN IN METASTATIC UTERINE LEIOMYOSARCOMA: A RETROSPECTIVE MULTICENTER STUDY OF THE SPANISH OVARIAN CANCER RESEARCH GROUP (GEICO)

Rubio, MJ; (...); Santaballa, A

Meeting Abstract. 2018


eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018


Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location

Seijas-Tamayo, R; (...); Cruz-Hernandez, JJ

Article. 10.1007/s12094-016-1493-1. 2016


EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019


Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project

Torregrosa, MD; (...); Ruiz, A

Article. 10.1007/s12094-019-02189-6. 2019


Experience of Home Delivery Program in Haemophilia Through an Association of Patients

Megias Vericat, J. E.; (...); Bonanad Boix, S.

Meeting Abstract. 2017


Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018


EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019


Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019


Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021


Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "ElA Alamo III" retrospective study

Marquez-Rodas, Ivan; (...); Lopez-Tarruella, Sara

Article. 10.1371/journal.pone.0184181. 2017


GEICO1601-ROLANDO trial: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Fidalgo, JAP; (...); Martin, AG

Meeting Abstract. 10.1016/j.annonc.2020.08.971. 2020


GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Perez-Fidalgo, JA; (...); Gonzalez-Martin, A

Article. 10.4155/fsoa-2018-0107. 2019


Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM).

Elez E; (...); Garrido P

Article. 10.1016/j.esmoop.2021.100048. 2021


Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024


Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022


Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017


Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018


Hazardous drugs: new challenges, new opportunities.

Valero García S; (...); Poveda Andrés JL

Article. 10.7399/fh.2016.40.2.10462. 2016


Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022


Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).

Alejandro Perez-Fidalgo, Jose; (...); Gonzalez-Martin, Antonio

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.5549. 2021


High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022


Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022


Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021


How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022


Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Rodríguez-Lescure Á; (...); de la Haba-Rodriguez J

Article. 10.1007/s12094-024-03411-w. 2024


Identification of a specific epigenetic signature in patients showing secondary hypertension upon anti-VEGF treatment from the GEICAM/2011-04 (BRECOL) study

de la Haba, J; (...); Rodriguez-Lescure, A

Meeting Abstract. 10.1158/1538-7445.SABCS19-P4-10-28. 2020


Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas

Salvador-Coloma, C; (...); de Mora, JF

Article. 10.2147/OTT.S214319. 2019


Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer

Salvador-Coloma, C; (...); de Mora, JF

Article. 10.1016/j.ejca.2020.08.020. 2020


Immunosuppressive profiles in liquid biopsy predict response to neoadjuvant chemotherapy in triple negative breast cancer

Salvador-Coloma, C; (...); Santaballa, A

Meeting Abstract. 10.1158/1538-7445.SABCS18-P3-11-16. 2019


Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017


Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis

Edo Solsona MD; (...); Poveda Andrés JL

Article. 10.2147/PPA.S127508. 2017


IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS

Edo-Solsona, M.; (...); Poveda-Andres, J.

Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016

  • Open Access.

Impact of an antimicrobial stewardship program on critical haematological patients.

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.7399/fh.2017.41.4.10709. 2017


Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1080/10428194.2020.1839650. 2020


Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018


Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017


Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020


Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019


Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020


Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018


Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

Zugazagoitia, J; (...); Manzano, A

Letter. 10.1183/13993003.02431-2017. 2018


Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018


Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016


Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019


Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017


Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018


Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021


Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.

Bermejo San José F; (...); Sanromán-Álvarez L

Article. 10.7399/fh.2016.40.5.10180. 2016


Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019


Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020


Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020


Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024


Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024


Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Alamo IV registry.

Martin, Miguel; (...); Aguiar-Bujanda, David

Article. 10.1007/s10549-023-07002-1. 2023


Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors

Salvador Coloma, C.; (...); Juan-Vidal, O.

Meeting Abstract. 2018


Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.

Kristeleit, Rebecca; (...); Subbiah, Vivek

Article. 10.1007/s10637-023-01383-2. 2023


Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.

Longo-Munoz, Federico; (...); Subbiah, Vivek

Article. 10.1016/j.ejca.2022.06.024. 2022


Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

  • Open Access.

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022


Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021


Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022


Metastatic urinary bladder involvement in breast cancer

Avargues A; (...); Boronat F

Article. 2015


Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020


Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.

Pena-Enriquez, Regina; (...); de la Haba-Rodriguez, Juan

Article. 10.1038/s41523-025-00718-x. 2025


Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021


Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021


Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018


Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

Romero, I; (...); Gonzalez-Martin, A

Article. 10.1097/CAD.0000000000000794. 2019


Multidisciplinary consensus on the criteria for fertility preservation in cancer patients.

Santaballa, A.; (...); Manau-Trullas, D.

Article. 10.1007/s12094-021-02699-2. 2022


Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021


National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021


National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022


Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

Fidalgo, JAP; (...); Gonzalez-Martin, A

Meeting Abstract. 10.1016/j.annonc.2021.08.1177. 2021


New clinical trials regulation in Spain: analysis of royal decree 1090/2015

Martin Jimenez M; (...); Segui Palmer MA

Article. 10.1007/s12094-016-1550-9. 2017


New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024


NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A GEICO STUDY WITHIN THE SPANISH EXTENDED ACCESS PROGRAM

Cueva Banuelos, J. F.; (...); Gonzalez-Martin, A.

Meeting Abstract. 10.1136/ijgc-2021-ESGO.447. 2021


Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022


ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023


Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

Perez-Fidalgo, JA; (...); Gonzalez-Martin, A

Article. 10.1016/j.esmoop.2021.100212. 2021


Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023


Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018


Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.

Garcia-Donas, Jesus; (...); Grande, Enrique

Article. 10.1007/s12094-023-03085-w. 2023


Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)

Santaballa, A; (...); Alba, E

Article. 10.1007/s12094-018-1951-z. 2019


OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024


OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis-An exploratory joint analysis of the BRCA and non-BRCA cohorts.

Selle, Frederic; (...); Pujade-Lauraine, Eric

Meeting Abstract. 2022


Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study

Ethier, JL; (...); Martin, M

Article. 10.1016/j.ejca.2018.02.018. 2018


Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.

Martin, Miguel; (...); Gil-Gil, Miguel

Article. 10.1016/j.ejca.2022.03.006. 2022


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

  • Open Access.

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.2174/1389200218666171101124931. 2018


Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016


Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021


Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022


Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.

Calleja Hernández MÁ; (...); Aragon, B

Article. 10.7399/fh.2017.41.1.10463. 2017


Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).

García-Donas J; (...); Navarro P

Article. 10.1016/j.ygyno.2024.10.019. 2024


Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL)

Garcia, YG; (...); Martin, AG

Meeting Abstract. 10.1200/JCO.2017.35.15_suppl.5508. 2017


Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)

Querol-Fuentes, F; (...); Bonanad, S

Meeting Abstract. 2017


Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018


PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020


Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial

Gustavo, Federico; (...); Albanell, Joan

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.1029. 2024


Plk1 expression & efficacy of palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03)

Guerrero-Zotano, A; (...); Martin, M

Meeting Abstract. 2021


Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial.

Mirza, MR; (...); Amant, F

Meeting Abstract. 10.1200/JCO.2017.35.15_suppl.TPS5613. 2017


Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018


Preclinical and clinical development of palbociclib and future perspectives

de Duenas, EM; (...); Llombart-Cussac, A

Review. 10.1007/s12094-018-1850-3. 2018


Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients

Martin, P; (...); Garde-Noguera, J

Meeting Abstract. 10.1016/j.jtho.2016.11.1880. 2017


Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

Garde-Noguera, J; (...); Juan-Vidal, O

Article. 10.1007/s12094-017-1829-5. 2018


Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients (vol 20, pg 1072, 2018)

Garde-Noguera, J; (...); Juan-Vidal, O

Correction. 10.1007/s12094-018-1916-2. 2018


PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019


Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021


Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021


Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

  • Open Access.

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021


Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)

Juan, O; (...); Codina, JG

Meeting Abstract. 10.1016/S1556-0864(18)30411-8. 2018


Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.

Antonio Mendez, Juan; (...); Juan Vidal, Oscar

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e21089. 2018


Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

Templeton, AJ; (...); GEICAM Study Investigators

Article. 10.1007/s12094-018-1885-5. 2018


Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1097/DSS.0000000000001046. 2017


Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2-endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study

Tibau, A; (...); Albanell, J

Meeting Abstract. 10.1016/j.annonc.2021.03.108. 2021


Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.

Tibau, Ariadna; (...); Albanell, Joan

Article. 10.1177/17588359221148921. 2023


Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018


Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).

Albanell, J.; (...); Rojo, F.

Article. 10.1016/j.ejca.2021.11.010. 2022


Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.

Harter P; (...); du Bois A

Article. 10.1056/NEJMoa2103294. 2021


Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)

Redondo, Andres; (...); Gonzalez-Martin, Antonio

Article. 10.31083/j.ejgo4206163. 2021


Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.

Cueva, Juan F.; (...); Gonzalez-Martin, Antonio

Article. 10.1016/j.ejca.2022.12.023. 2022


Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.

Cuéllar Monreal MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.2017.41.1.10434. 2017


Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer

Estal, RM; (...); Gilabert, PB

Article. 10.1007/s10689-015-9864-2. 2016


Replied to "Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)".

Virizuela JA; (...); Fernández TL

Letter. 10.1007/s12094-019-02173-0. 2019


Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.

Alvarez-Lopez I; (...); Santaballa Bertrán A

Review. 10.1007/s12094-019-02269-7. 2020


Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification

Salvador Coloma, C.; (...); Juan-Vidal, O.

Meeting Abstract. 2018


Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial

Perez-Fidalgo, Jose Alejandro; (...); Gonzalez-Martin, Antonio

Meeting Abstract. 2024


Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program.

Yubero, Alfonso; (...); Gonzalez-Martin, Antonio

Case Reports. 10.1016/j.gore.2023.101211. 2023


Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study

Yubero, Alfonso; (...); Gonzalez-Martin, Antonio

Article. 10.1186/s12885-022-10191-5. 2022


Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018


SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020


SEOM clinical guideline for secondary prevention (2019).

Santaballa A; (...); Bayo J

Article. 10.1007/s12094-020-02302-0. 2020


SEOM Clinical Guideline in ovarian cancer (2016)

Santaballa, A; (...); Romero, I

Article. 10.1007/s12094-016-1588-8. 2016


SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016)

Munoz M; (...); Blasco A

Article. 10.1007/s12094-016-1587-9. 2016


SEOM clinical guidelines for endometrial cancer (2017)

Santaballa, A; (...); Gonzalez-Martin, A

Article. 10.1007/s12094-017-1809-9. 2018


SEOM clinical guidelines for endometrial cancer (2017) (vol 20, pg 29, 2018)

Santaballa, A; (...); Gonzalez-Martin, A

Correction. 10.1007/s12094-018-1842-3. 2018


SEOM clinical guidelines in gestational trophoblastic disease (2017)

Santaballa, A; (...); Garcia-Martinez, E

Article. 10.1007/s12094-017-1793-0. 2018


SEOM clinical guidelines on cardiovascular toxicity (2018)

Virizuela, JA; (...); Fernandez, TL

Article. 10.1007/s12094-018-02017-3. 2019


SEOM clinical guidelines to primary prevention of cancer (2018).

Bayo J; (...); Santaballa A

Article. 10.1007/s12094-018-02016-4. 2019


SEOM guidelines 2016: an update

Santaballa, A, Martin, M

Editorial Material. 10.1007/s12094-016-1592-z. 2016


SEOM guidelines 2018

Santaballa, A, Vera, R

Editorial Material. 10.1007/s12094-018-02024-4. 2019


SEOM-GEICO clinical guidelines on endometrial cancer (2021).

Barretina-Ginesta MP; (...); Rubio-Pérez MJ

Article. 10.1007/s12094-022-02799-7. 2022


Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

Aguas Peris M; (...); Nos, P

Article. 10.1097/MIB.0000000000001182. 2017


Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice

Aguas, M; (...); Nos, P

Meeting Abstract. 2017


SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022


Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry).

Lopez-Tarruella S; (...); Carrasco E

Article. 10.1038/s41598-019-55765-9. 2019


Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022


The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022


The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022


The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).

Pizarro, David; (...); Palacios, Jose

Article. 10.3390/ijms241311183. 2023


The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024


The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018


Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020


Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?

Bejar, S; (...); Mateu, PN

Meeting Abstract. 2020


Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy

Garcia, SV; (...); Andres, JLP

Article. 10.1016/j.yrtph.2018.10.002. 2018


Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients

García-Robles AA; (...); Poveda JL

Letter. 10.1016/j.jns.2016.04.048. 2016


USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Dominguez Hernandez, L.; (...); Gomez Segui, I

Meeting Abstract. 2019

  • Open Access.

Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial

Albanell, Joan; (...); Rojo Todo, Federico Gustavo

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.1028. 2024


VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023


Campos de estudio

Compartir